Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 37

1.

Skeletal Muscle Glycogen Chain Length Correlates with Insolubility in Mouse Models of Polyglucosan-Associated Neurodegenerative Diseases.

Sullivan MA, Nitschke S, Skwara EP, Wang P, Zhao X, Pan XS, Chown EE, Wang T, Perri AM, Lee JPY, Vilaplana F, Minassian BA, Nitschke F.

Cell Rep. 2019 Apr 30;27(5):1334-1344.e6. doi: 10.1016/j.celrep.2019.04.017.

2.

Embryo movements regulate tendon mechanical property development.

Pan XS, Li J, Brown EB, Kuo CK.

Philos Trans R Soc Lond B Biol Sci. 2018 Sep 24;373(1759). pii: 20170325. doi: 10.1098/rstb.2017.0325.

3.

Roadmap of molecular, compositional, and functional markers during embryonic tendon development.

Nguyen PK, Pan XS, Li J, Kuo CK.

Connect Tissue Res. 2018 Sep;59(5):495-508. doi: 10.1080/03008207.2018.1511710. Epub 2018 Sep 20.

PMID:
30231651
4.

Trapping of the transport-segment DNA by the ATPase domains of a type II topoisomerase.

Laponogov I, Pan XS, Veselkov DA, Skamrova GB, Umrekar TR, Fisher LM, Sanderson MR.

Nat Commun. 2018 Jul 3;9(1):2579. doi: 10.1038/s41467-018-05005-x.

5.

Exploring the active site of the Streptococcus pneumoniae topoisomerase IV-DNA cleavage complex with novel 7,8-bridged fluoroquinolones.

Laponogov I, Pan XS, Veselkov DA, Cirz RT, Wagman A, Moser HE, Fisher LM, Sanderson MR.

Open Biol. 2016 Sep;6(9). pii: 160157.

6.

Structure of a quinolone-stabilized cleavage complex of topoisomerase IV from Klebsiella pneumoniae and comparison with a related Streptococcus pneumoniae complex.

Veselkov DA, Laponogov I, Pan XS, Selvarajah J, Skamrova GB, Branstrom A, Narasimhan J, Prasad JV, Fisher LM, Sanderson MR.

Acta Crystallogr D Struct Biol. 2016 Apr;72(Pt 4):488-96. doi: 10.1107/S2059798316001212. Epub 2016 Mar 24.

7.

Structure of an 'open' clamp type II topoisomerase-DNA complex provides a mechanism for DNA capture and transport.

Laponogov I, Veselkov DA, Crevel IM, Pan XS, Fisher LM, Sanderson MR.

Nucleic Acids Res. 2013 Nov;41(21):9911-23. doi: 10.1093/nar/gkt749. Epub 2013 Aug 21.

8.

Functional determinants of gate-DNA selection and cleavage by bacterial type II topoisomerases.

Arnoldi E, Pan XS, Fisher LM.

Nucleic Acids Res. 2013 Nov;41(20):9411-23. doi: 10.1093/nar/gkt696. Epub 2013 Aug 12.

9.

Cooperation during cultural group formation promotes trust towards members of out-groups.

Pan XS, Houser D.

Proc Biol Sci. 2013 May 8;280(1762):20130606. doi: 10.1098/rspb.2013.0606. Print 2013 Jul 7.

10.

The causal effect of market priming on trust: an experimental investigation using randomized control.

Al-Ubaydli O, Houser D, Nye J, Paganelli MP, Pan XS.

PLoS One. 2013;8(3):e55968. doi: 10.1371/journal.pone.0055968. Epub 2013 Mar 5.

11.

Competition for trophies triggers male generosity.

Pan XS, Houser D.

PLoS One. 2011 Apr 6;6(4):e18050. doi: 10.1371/journal.pone.0018050.

12.

Structural basis of gate-DNA breakage and resealing by type II topoisomerases.

Laponogov I, Pan XS, Veselkov DA, McAuley KE, Fisher LM, Sanderson MR.

PLoS One. 2010 Jun 28;5(6):e11338. doi: 10.1371/journal.pone.0011338. Erratum in: PLoS One. 2010;5(7) doi: 10.1371/annotation/deacc2fd-665b-4736-b668-dc69a38bb4f9.

13.

[Study on the morbidity rates of hypertension and metabolic syndrome among Zhuang adults in Baise area].

Li TZ, Pan XS, Lu KX.

Zhonghua Liu Xing Bing Xue Za Zhi. 2009 Jul;30(7):755-7. Chinese. No abstract available.

PMID:
19957611
14.

Probing the differential interactions of quinazolinedione PD 0305970 and quinolones with gyrase and topoisomerase IV.

Pan XS, Gould KA, Fisher LM.

Antimicrob Agents Chemother. 2009 Sep;53(9):3822-31. doi: 10.1128/AAC.00113-09. Epub 2009 Jun 29.

15.

Structural insight into the quinolone-DNA cleavage complex of type IIA topoisomerases.

Laponogov I, Sohi MK, Veselkov DA, Pan XS, Sawhney R, Thompson AW, McAuley KE, Fisher LM, Sanderson MR.

Nat Struct Mol Biol. 2009 Jun;16(6):667-9. doi: 10.1038/nsmb.1604. Epub 2009 May 17.

PMID:
19448616
16.

Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.

Cambau E, Matrat S, Pan XS, Roth Dit Bettoni R, Corbel C, Aubry A, Lascols C, Driot JY, Fisher LM.

J Antimicrob Chemother. 2009 Mar;63(3):443-50. doi: 10.1093/jac/dkn528. Epub 2009 Jan 15.

PMID:
19147516
17.

The difficult case of crystallization and structure solution for the ParC55 breakage-reunion domain of topoisomerase IV from Streptococcus pneumoniae.

Sohi MK, Veselkov DA, Laponogov I, Pan XS, Fisher LM, Sanderson MR.

PLoS One. 2008 Sep 12;3(9):e3201. doi: 10.1371/journal.pone.0003201.

18.

Clerocidin selectively modifies the gyrase-DNA gate to induce irreversible and reversible DNA damage.

Pan XS, Dias M, Palumbo M, Fisher LM.

Nucleic Acids Res. 2008 Oct;36(17):5516-29. doi: 10.1093/nar/gkn539. Epub 2008 Aug 22.

19.

Methods to assay inhibitors of DNA gyrase and topoisomerase IV activities.

Fisher LM, Pan XS.

Methods Mol Med. 2008;142:11-23. doi: 10.1007/978-1-59745-246-5_2.

PMID:
18437302
20.

Breakage-reunion domain of Streptococcus pneumoniae topoisomerase IV: crystal structure of a gram-positive quinolone target.

Laponogov I, Veselkov DA, Sohi MK, Pan XS, Achari A, Yang C, Ferrara JD, Fisher LM, Sanderson MR.

PLoS One. 2007 Mar 21;2(3):e301.

21.

[Study on the level of peroxidation in tunnel workers and protective effect of orally vitamin C and vitamin E].

Liu AS, Pan XS, Hu DJ.

Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 2005 Jun;23(3):210-1. Chinese. No abstract available.

PMID:
16124902
22.

Novel symmetric and asymmetric DNA scission determinants for Streptococcus pneumoniae topoisomerase IV and gyrase are clustered at the DNA breakage site.

Leo E, Gould KA, Pan XS, Capranico G, Sanderson MR, Palumbo M, Fisher LM.

J Biol Chem. 2005 Apr 8;280(14):14252-63. Epub 2005 Jan 18.

23.

Ciprofloxacin dimers target gyrase in Streptococcus pneumoniae.

Gould KA, Pan XS, Kerns RJ, Fisher LM.

Antimicrob Agents Chemother. 2004 Jun;48(6):2108-15.

24.

Mycobacterium tuberculosis DNA gyrase: interaction with quinolones and correlation with antimycobacterial drug activity.

Aubry A, Pan XS, Fisher LM, Jarlier V, Cambau E.

Antimicrob Agents Chemother. 2004 Apr;48(4):1281-8.

25.

Analysis of dual active fluoroquinolones in Streptococcus pneumoniae.

Fisher LM, Gould KA, Pan XS, Patel S, Heaton VJ.

J Antimicrob Chemother. 2003 Aug;52(2):312-3; author reply 313-4. Epub 2003 Jul 15. No abstract available.

PMID:
12865396
26.

Small-colony mutants of Staphylococcus aureus allow selection of gyrase-mediated resistance to dual-target fluoroquinolones.

Pan XS, Hamlyn PJ, Talens-Visconti R, Alovero FL, Manzo RH, Fisher LM.

Antimicrob Agents Chemother. 2002 Aug;46(8):2498-506.

28.
32.
34.

Involvement of topoisomerase IV and DNA gyrase as ciprofloxacin targets in Streptococcus pneumoniae.

Pan XS, Ambler J, Mehtar S, Fisher LM.

Antimicrob Agents Chemother. 1996 Oct;40(10):2321-6.

36.

Twenty-one cases of phenylketonuria out of 358,767 newborns in Shanghai, China.

Chen RG, Pan XS, Qian DL, Guo H.

J Inherit Metab Dis. 1989;12(4):485. No abstract available.

PMID:
2516180
37.

Neonatal hypothyroidism, phenylketonuria and galactosemia screening in metropolitan Shanghai.

Chen RG, Sun M, Ni YY, Pan XS, Chen JZ, Zhang YF, Liu H, Zhang MH, Xu HZ, Wu YL, et al.

Chin Med J (Engl). 1984 Jan;97(1):61-5. No abstract available.

PMID:
6428834

Supplemental Content

Support Center